If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Emgality Summary of Product Characteristics (SmPC)
In patients taking Emgality® ▼(galcanezumab) and planning a pregnancy, is a washout needed?
There is no information on which to base a recommendation for a washout period for those who are receiving galcanezumab and are planning to become pregnant.
to Become Pregnant: Washout Period
is an IgG4 monoclonal antibody and is expected to be degraded into
small peptides and amino acids via catabolic pathways in the same
manner as endogenous IgG.1,2
should use their clinical judgment in determining the most
appropriate approach in a patient treated with galcanezumab who is
planning to become pregnant.
from the label
are limited data from the use of galcanezumab in pregnant women.
Animal studies do not indicate direct or indirect harmful effects
with respect to reproductive toxicity.1
effect of galcanezumab on human fertility has not been evaluated.
Fertility studies in animals do not indicate harmful effects with
respect to male and female fertility.1
Emgality [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and
pharmacodynamic insights into monoclonal antibodies with a focus on
galcanezumab, an anti-CGRP antibody. Cephalalgia.
= immunoglobulin G
= immunoglobulin G (subclass) 4
= elimination half-life
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:January 11, 2021
Are you satisfied with this content?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at email@example.com